Published in Law and Health Weekly, February 5th, 2005
On December 23, 2004, Tercica Inc. and its licensor, Genentech, filed a lawsuit in the U.S. District Court for Northern California against Insmed challenging Insmed's right to commercialize its proprietary IGF-I replacement hormone, SomatoKine, in the United States and seeking damages for alleged patent infringement by Insmed's predecessor, Celtrix, of certain patents licensed to Tercica.
Tercica also filed a lawsuit in the United Kingdom against Insmed and its contract manufacturer, Avecia, that was announced last week.
In response to these events, Insmed's chief...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.